Abstract | BACKGROUND:
Aspirin is a key antiplatelet therapy for the prevention of thrombotic events in patients with cardiovascular disease. Studies suggest that ≈20% of patients with cardiac disease suffer from aspirin nonsensitivity, a phenomenon characterized by the inability of 81 mg aspirin to inhibit platelet aggregation and/or prevent adverse cardiovascular events. OBJECTIVES: METHODS: RESULTS: Of the 150 patients recruited, 36 patients (24%) were nonsensitive to 81 mg of aspirin. Of these 36 nonsensitive patients, 30 patients provided a urine sample for urine salicyluric acid analysis (a major metabolite of aspirin). Urine analysis demonstrated that 14 patients were compliant and 16 were noncompliant with their aspirin therapy. Major adverse cardiovascular events and major adverse limb events were significantly higher in the nonsensitive patients compared to sensitive patients (hazard ratio, 3.68; P < 0.001). CONCLUSION: These data highlight the high prevalence of aspirin nonsensitivity and noncompliance in patients with vascular disease and emphasizes the urgent need for improved medical management options for this patient population.
|
Authors | Hamzah Khan, Abdelrahman Zamzam, Reid C Gallant, Muzammil H Syed, Margaret L Rand, Heyu Ni, Thomas L Forbes, Mohammed Al-Omran, Mohammad Qadura |
Journal | Research and practice in thrombosis and haemostasis
(Res Pract Thromb Haemost)
Vol. 5
Issue 8
Pg. e12618
(Dec 2021)
ISSN: 2475-0379 [Electronic] United States |
PMID | 34816074
(Publication Type: Journal Article)
|
Copyright | © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). |